Degradation of B-Myb by ubiquitin-mediated proteolysis:: involvement of the Cdc34-SCFp45Skp2 pathway

被引:72
作者
Charrasse, S
Carena, I
Brondani, V
Klempnauer, KH
Ferrari, S
机构
[1] Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland
[2] Univ Munster, Inst Biochem, D-48149 Munster, Germany
关键词
B-Myb; ubiquitination; p45(Skp2); cyclin A;
D O I
10.1038/sj.onc.1203618
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
B-Myb, a highly conserved member of the Myb oncoprotein family, is a 110 kDa sequence-specific DNA binding protein expressed in virtually all proliferating cells, B-myb expression reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle. We have previously shown that B-Myb activity is cell cycle regulated and it is controlled by the antagonistic effects of cyclin Dt and A. Here we show that ectopic expression of cyclin A causes a pronounced reduction of B-Myb protein level, We provide evidence that in addition to triggering B-Myb activity an important effect of cyclin A is to facilitate multiple ubiquitination of B-Myb, The C-terminal domain of B-Myb is of key importance in mediating this effect of cyclin A, Contrary to full-length B-Myb, a C-terminal deletion mutant displays activity irrespective of cyclin A expression, does not undergo ubiquitination, and its half-life is not affected by cyclin A. Ectopic expression of either Cdc34 or the F-box protein p45(Skp2), respectively the E2 and E3 components of a ubiquitination pathway that regulates the G1/S transition, accelerates degradation of B-Myb, We show that B-Myb physically and functionally interacts with components of the Cdc34-SCFp45Skp2 ubiquitin pathway and propose that B-Myb degradation may be required for controlling the correct alternation of events during progression through the cell division cycle.
引用
收藏
页码:2986 / 2995
页数:10
相关论文
共 58 条
[31]   Substrate targeting in the ubiquitin system [J].
Laney, JD ;
Hochstrasser, M .
CELL, 1999, 97 (04) :427-430
[32]  
LEBWOHL DE, 1994, ONCOGENE, V9, P1925
[33]   CONSTITUTIVE EXPRESSION OF B-MYB CAN BYPASS P53-INDUCED WAF1/CIP1-MEDIATED G(1) ARREST [J].
LIN, D ;
FISCELLA, M ;
OCONNOR, PM ;
JACKMAN, J ;
CHEN, M ;
LUO, LL ;
SALA, A ;
TRAVALI, S ;
APPELLA, E ;
MERCER, WE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :10079-10083
[34]   Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45SKP2:: evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway [J].
Lisztwan, J ;
Marti, A ;
Sutterlüty, H ;
Gstaiger, M ;
Wirbelauer, C ;
Krek, W .
EMBO JOURNAL, 1998, 17 (02) :368-383
[35]   Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas [J].
Loda, M ;
Cukor, B ;
Tam, SW ;
Lavin, P ;
Fiorentino, M ;
Draetta, GF ;
Jessup, JM ;
Pagano, M .
NATURE MEDICINE, 1997, 3 (02) :231-234
[36]   SIGNALING AND SUPERINDUCTION [J].
MAHADEVAN, LC ;
EDWARDS, DR .
NATURE, 1991, 349 (6312) :747-748
[37]  
MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280
[38]   Cyclin-dependent kinases: Engines, clocks, and microprocessors [J].
Morgan, DO .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1997, 13 :261-291
[39]   ISOLATION OF HUMAN CDNA CLONES OF MYB-RELATED GENES, A-MYB AND B-MYB [J].
NOMURA, N ;
TAKAHASHI, M ;
MATSUI, M ;
ISHII, S ;
DATE, T ;
SASAMOTO, S ;
ISHIZAKI, R .
NUCLEIC ACIDS RESEARCH, 1988, 16 (23) :11075-11089
[40]   ROLE OF THE UBIQUITIN-PROTEASOME PATHWAY IN REGULATING ABUNDANCE OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P27 [J].
PAGANO, M ;
TAM, SW ;
THEODORAS, AM ;
BEERROMERO, P ;
DELSAL, G ;
CHAU, V ;
YEW, PR ;
DRAETTA, GF ;
ROLFE, M .
SCIENCE, 1995, 269 (5224) :682-685